| Abstract | Pneumocystis carinii pneumonia continues to be a cause of morbidity and mortality in AIDS patients. Current therapies have a high rate of toxicity and failure. Compound 566C80 is a 1-4,hydroxynaphthoquinone with potent antiprotozoal activity which shows good efficacy and safety in 21-day treatment trials of P. carinii pneumonia (PCP) in AIDS patients. Because there is a generally high recurrence rate after treatment of PCP and there may be a possible advantage in decreasing the P. carinii burden in the lung with extended anti-Pneumocystis therapy, we performed an open label-trial of the safety and efficacy of 42-day therapy with 566C80 for PCP in AIDS patients. Ten patients were enrolled and one was lost to follow-up. Eight of the remaining nine patients successfully completed 42 days of therapy with minimal toxicity. This trial suggests that 566C80 for 42 days can be an effective, safe, and well-tolerated oral therapy for PCP in AIDS patients. |
| Authors | M N Dohn, P T Frame, R P Baughman, S W Lafon, A G Smulian, P Caldwell, M D Rogers
(Affiliation: University of Cincinnati Medical Center, Ohio 45267-0564.)
|
| Journal | The Journal of protozoology
(J Protozool)
1991 Nov-Dec
Vol. 38
Issue 6
Pg. 220S-221S
ISSN: 0022-3921 UNITED STATES |
| PMID | 1818178
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
| Chemical References |
- Antifungal Agents
- Naphthoquinones
- Atovaquone
|
| Topics |
- Acquired Immunodeficiency Syndrome
(complications)
- Administration, Oral
- Antifungal Agents
(adverse effects, therapeutic use)
- Atovaquone
- Bronchoalveolar Lavage Fluid
- Drug Tolerance
- Follow-Up Studies
- Food
- Humans
- Male
- Naphthoquinones
(adverse effects, therapeutic use)
- Pneumonia, Pneumocystis
(complications, drug therapy)
- Recurrence
- Time Factors
|
